Vericel (VCEL) Cash from Financing Activities (2010 - 2026)
Vericel's (VCEL) quarterly Cash from Financing Activities came in at -$3.0 million in Q1 2026, down 193.15% year-on-year from $3.2 million in Q1 2025, and down 379.72% quarter-over-quarter from $1.1 million in Q4 2025.
Vericel (VCEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vericel has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$3.0 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$3.0 million, down 193.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $893000.0 (down 95.56% YoY), and the FY2025 annual result was $7.1 million, down 62.89% from the prior year.
- Cash from Financing Activities came in at -$3.0 million for Q1 2026 at Vericel, down from $1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q4 2024 to a low of -$3.0 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $1.2 million (2025), against an average of $1.6 million.
- Across the five-year window, Cash from Financing Activities surged 1886.92% in 2024 and sank 193.15% in 2026, its largest moves.
- Vericel's Cash from Financing Activities stood at $605000.0 in 2022, then surged by 116.03% to $1.3 million in 2023, then surged by 443.84% to $7.1 million in 2024, then sank by 85.02% to $1.1 million in 2025, then tumbled by 379.72% to -$3.0 million in 2026.
- The last three Cash from Financing Activities figures came in at -$3.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | -2.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.98 Mn |
| Mar 31, 2026 | -2.98 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |